Dextromethorphan and Fluoxetine for the treatment of OCD
Phase 2
Recruiting
- Conditions
- Obsessive-compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT20090117001556N158
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age between 18 to 60 years old
Diagnosis of OCD based on DSM-5
Score of >21 in Yale–Brown obsessive-compulsive scale (Y-BOCS)
Exclusion Criteria
Receiving any treatment up to 6 weeks before the start of the trial
Diagnosis of another psychiatric disorder
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of dextromethorphan-fluoxetine combination in OCD treatment?
How does dextromethorphan-fluoxetine compare to SSRIs and SNRIs in treating moderate to severe OCD?
Are there specific biomarkers that predict response to dextromethorphan-fluoxetine combination therapy for OCD?
What are the potential adverse events associated with dextromethorphan-fluoxetine combination therapy for OCD?
What other NMDA receptor modulators or serotonin reuptake inhibitors are being explored for OCD treatment alongside Tehran University of Medical Sciences research?